-The Economic Times Indian pharmaceutical company Ranbaxy recently paid $500 million to the US government to settle civil and criminal charges for making fraudulent statements to the US FDA and selling adulterated drugs in the US. Dinesh Thakur, an ex-Ranbaxy employee who blew the whistle on the company, talks to ET about the five-year long investigation and the future of generic drug companies in the US. Edited Excerpts: * You think you...

-The Business Standard Patient safety & quality our guidance now, says Sawhney Trouble-hit Ranbaxy Laboratories has introduced a whistle-blower policy within the company to encourage transparency and address concerns internally, so that bigger problems could be averted. In his first interaction with the media (the first part of which was published on Sunday) since the drug maker pleaded guilty of making fraudulent statements to the US Food and Drugs Administration (FDA) under its...

-Frontline The Central government's proposal to hand over the supply of supplementary nutrition to NGOs in the name of "community participation" is surely an invitation for private profiteering on the back of this supposedly public scheme. ENSURING safe and healthy conditions for the reproduction of the population is obviously the most fundamental requirement of any society. So the progress of a society can be determined (and indeed is routinely judged) by the...

-The Hindu Ranbaxy, one of India's largest pharmaceutical companies, has agreed to pay $500 million fines levied by U.S. authorities for selling adulterated drugs and lying to federal regulators in a case that is part of an ongoing crackdown on the quality of generic drugs flowing into the U.S. The deal struck on Monday, said to be the largest financial penalty against a generic drug company for violations of FDA standards, came...

-The Hindu It cannot get any worse than this. Over three lakh newborns in India die on the very first day of their birth. With this the country ranks as number one in terms of first day of birth mortality; its share in global first-day deaths stands at 29 per cent. The appalling state of Indian health care to which this speaks is further highlighted by the fact that the...